Filing Date Form TypeDescription   
   
Data pager
 Page 1 of 15, items 1 to 13 of 189.
2022-05-124Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-22-004878 Size: 6 KB
2022-05-1210-QQuarterly report [Sections 13 or 15(d)]Acc-no: 0001213900-22-025962 (34 Act)  Size: 3 MB
2022-05-058-KCurrent report, items 2.02 and 9.01 Acc-no: 0001213900-22-024232 (34 Act)  Size: 306 KB
2022-04-29DEF 14AOther definitive proxy statementsAcc-no: 0001213900-22-022569 (34 Act)  Size: 4 MB
2022-03-2510-KAnnual report [Section 13 and 15(d), not S-K Item 405]Acc-no: 0001213900-22-015172 (34 Act)  Size: 5 MB
2022-03-114Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-22-002898 Size: 8 KB
2022-03-104Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-22-002820 Size: 8 KB
2022-03-104Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-22-002818 Size: 4 KB
2022-03-098-KCurrent report, items 8.01 and 9.01 Acc-no: 0001213900-22-011247 (34 Act)  Size: 220 KB
2022-03-084Statement of changes in beneficial ownership of securitiesAcc-no: 0001415889-22-002727 Size: 9 KB
2022-03-038-KCurrent report, items 1.01, 2.01, and 9.01 Acc-no: 0001213900-22-010531 (34 Act)  Size: 464 KB
2022-02-108-KCurrent report, items 2.02 and 9.01 Acc-no: 0001213900-22-006461 (34 Act)  Size: 390 KB
2022-02-07SC 13G/A[Amend] Statement of acquisition of beneficial ownership by individualsAcc-no: 0001493152-22-003332 (34 Act)  Size: 81 KB


Sensus Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237%
05/05/2022 8:05 PM

Diluted EPS from operations of $0.20 compare with $(0.07) in the year-ago quarter


Sensus Healthcare to Host First Quarter 2022 Financial Results and Business Update Conference Call on May 5, 2022
04/21/2022 12:00 PM

BOCA RATON, Fla, April 21, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 5, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Mata Mata Turtle with Squamous Cell Carcinoma Successfully Treated with Sensus Healthcare’s SRT System by Colorado State University Veterinarian
03/24/2022 12:00 PM

Joins multiple companion animals and a horse successfully treated with SRT
Joins multiple companion animals and a horse successfully treated with SRT

Sensus Healthcare to Present at Two Investment Conferences in March
03/09/2022 9:05 PM

BOCA RATON, Fla. , March 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will be presenting at the following investment conferences during March:


Sensus Healthcare Announces Share Repurchase Program
03/09/2022 1:00 PM

BOCA RATON, Fla, March 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors has authorized a program to purchase up to $3,000,000 of shares of its Common Stock. 


Sensus Healthcare Sells its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash
03/02/2022 1:00 PM

Sale permits Sensus to focus on the core dermatology market while providing capital for channel expansion


Sensus Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter
02/10/2022 9:05 PM

4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively


Sensus Healthcare Prepares Organization for Long-term Growth with Three Promotions
01/31/2022 9:05 PM

Michael J. Sardano named President, Christopher Machuzak and Jeffrey Starling named Regional Vice Presidents of Sales
Michael J. Sardano named President, Christopher Machuzak and Jeffrey Starling named Regional Vice Presidents of Sales

Sensus Healthcare to Host Fourth Quarter 2021 Financial Results and Business Update Conference Call on February 10, 2022
01/26/2022 1:30 PM

BOCA RATON, Fla, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 10, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Sensus Healthcare to Present at the H.C. Wainwright BioConnect Virtual Conference
01/06/2022 6:08 PM

Company Management Available for 1x1 Meetings Concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14
Company Management Available for 1x1 Meetings Concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14

Sensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference
01/05/2022 1:00 PM

Expects profitability for the 2021 fourth quarter and full year Physician KOL presentation at the Winter Clinical to highlight the TransDermal Infusion System™
Expects profitability for the 2021 fourth quarter and full year Physician KOL presentation at the Winter Clinical to highlight the TransDermal Infusion System™

Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System
12/01/2021 1:30 PM

Sensus to Bring FDA-cleared Non-invasive Drug-delivery System and Treatment Alternative to Needles to Dermatologists Beginning [Immediately/Date]
Sensus to Bring FDA-cleared Non-invasive Drug-delivery System and Treatment Alternative to Needles to Dermatologists Beginning [Immediately/Date]

Sensus Healthcare Reports Third Quarter 2021 Financial Results
11/04/2021 8:02 PM

Achieves profitability on revenues of $5.5 million, up sharply from $1.6 million a year ago


Sensus Healthcare to Host Third Quarter 2021 Financial Results and Business Update Conference Call on November 4, 2021
10/20/2021 12:30 PM

BOCA RATON, Fla, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 4, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.


Sensus Healthcare to Participate in Fireside Chat Hosted by Maxim Group and M-Vest
10/15/2021 12:30 PM

Fireside Chat with CEO Joe Sardano and CFO Javier Rampolla will be held October 19, 2021 at 11:00 a.m. ET
Fireside Chat with CEO Joe Sardano and CFO Javier Rampolla will be held  October 19, 2021 at 11:00 a.m. ET

Chinese Health Authority Renews License for Sensus Healthcare’s SRT-100™ for Five More Years
10/12/2021 12:30 PM


Sensus Healthcare Announces Presentations, Demonstrations and Exhibit Booth at the 2021 Fall Clinical Conference in Las Vegas
10/07/2021 12:30 PM

Premier gathering expected to host more than 1,200 physicians with 500 virtual participants is the first in-person dermatology medical conference in 18 months


Sensus Healthcare to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
09/08/2021 1:00 PM

Boca Raton, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that Joe Sardano, chairman and chief executive officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13 – 15, 2021.


Sensus Healthcare Reports Second Quarter 2021 Financial Results
08/05/2021 8:05 PM

Revenues of $5.4 million up 358% year-over-year, up 77% sequentially


Sensus Healthcare to Host Second Quarter 2021 Financial Results and Business Update Conference Call on August 5, 2021
07/29/2021 12:00 PM

BOCA RATON, Fla, July 29, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2021. In addition, management will provide a business update and a discussion on recent and upcoming milestones.